# Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

> **NCT02289690** · PHASE1,PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 221 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Veliparib
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02289690
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-13
- **Primary completion:** 2019-04-17
- **Final completion:** 2019-04-17
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2020-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02289690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02289690, "Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02289690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*